Hemophilia Drugs Market To Expand By 2028 As FDA Approves New Drugs For Sale In The Market
Research Nester released a report titled “Hemophillia A Drugs Market: Global Demand Analysis & Opportunity Outlook 2028” which delivers detailed overview of the global hemophilia A drugs market in terms of market segmentation by product, by route of administration, by distribution channel and by region.
Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.
The market for hemophilia A drugs is anticipated to record a significantly high CAGR over the forecast period, i.e., 2020-2028. Hemophilia is a condition in which the body is not able to form blood clots in order to stop bleeding. The market is segmented by product, by route of administration, by distribution channel and by region. The product segment is further segmented into plasma derived coagulation factor concentrate, recombinant coagulation factor concentrates, antifibrinolytics, desmopressin and others, out of which, the segment for plasma derived coagulation factors is anticipated to hold the largest share in the hemophilia A drugs market. The segment for route of administration is further segmented into intravenous, oral, nasal and others, out of which, the intravenous segment currently holds the largest share in the market.
Based on region, the hemophilia A drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Hemophilia A drugs market in North America is projected to hold the leading share in the market. This can be attributed to the recent advancements in the healthcare industry as well as the research and development of new drugs.The market in Asia Pacific, however, is estimated to observe the highest growth rate over the forecast period as a result of rising number of patients with hemophilia A.
Download Sample of This Strategic Report
Rising Awareness About Hemophilia to Boost the Market Growth
According to the National Hemophilia Foundation, Hemophilia A occurs in 1 out of 5,000 live male births in the United States. Additionally, hemophilia A is four times more common than hemophilia B. About 20,000 people in the United States are estimated to have hemophilia. Globally, around 400,000 people are predicted to be hemophilic. The report mentioned that approximately 75% of people with hemophilia do not receive proper treatment. The market is anticipated to witness significant growth as a result of growing cases of the condition. However, the high costs associated with the drugs as well as the therapies available for hemophilia A treatment is predicted to restrain the market growth over the forecast period.
This report also provides the existing competitive scenario of some of the key players of the global hemophilia A drugs market which includes company profiling of Pfizer Inc., Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd, Novo Nordisk A/S, Genzyme Corporation, Grifols, S.A., CSL Behring, Octapharma AG, Aptevo Therapeutics and Ferring Pharmaceuticals. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global hemophilia A drugs market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.
- Research Nester
- Pooja Singh
- Website: Hemophilia Drugs Market